PARP1 and hyperinsulinemic hypoglycemia, familial, 4: Furthermore, we suggest that an inhibitor demonstrating significant PARP1 trapping capability along with potent PARylation inhibition will be the most effective as a single agent for cancers characterised by HRR deficiency.